News

The proposed $34 price reflects a $2 per share increase and Lilly has said that this is its best and final offer. Indianapolis-based Lilly is keen to extend

The payment will include equipment and inventory payments and gives ZLB Behring full worldwide rights to CytoGam. CytoGam is an intravenous immune globulin enriched in antibodies against cytomegalovirus

As part of the collaboration, Exelixis will be fully responsible for the identification and preclinical development of small molecule drug candidates directed against mutually selected targets. Bristol-Myers Squibb

Somaxon believes that the product has potential to become a significant participant in the insomnia market. With the conclusion of this trial, Somaxon has completed six clinical trials

Merck agreed to buy the Bertarelli family’s 64.5% stake in Serono in September 2006. Merck had originally turned its attention to the acquisition of Serono after it lost

The drug is already indicated for adults with rheumatoid arthritis. Celebrex is a medication which is part of a class of drugs known as COX-2 inhibitors. COX-2 inhibitors,

Treatment with Tracleer in mildly symptomatic pulmonary arterial hypertension (PAH) patients was associated with a highly significant reduction in pulmonary vascular resistance compared to placebo, a primary endpoint

Foradil Certihaler was recalled from the German and Swiss markets in January 2006 because of concerns that accidental mishandling of the device may have resulted in inaccurate dosing

The interim analysis from the head-to-head trial also showed that weekly Abraxane nearly doubled the response rate with less toxicity compared to Abraxane dosed every three weeks. Although